| Name | Title | Contact Details |
|---|---|---|
Giacomo Salvadore |
Chief Medical Officer | Profile |
Ja Moon |
VP, Healthcare Legal and Compliance | Profile |
Brian Sander |
General Counsel | Profile |
Kristina Vlaovic |
Vice President Regulatory Affairs | Profile |
Danielle Pasqualone |
Vice President, Intellectual Property | Profile |
Since our beginning in 1948, the Framingham Heart Study, under the direction of the National Heart, Lung and Blood Institute (NHLBI), formerly known as the National Heart Institute, has been committed to identifying the common factors or characteristics that contribute to cardiovascular disease (CVD). We have followed CVD development over a long period of time in three generations of participants.
Riverland Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Ferriday, LA. To find more information about Riverland Medical Center, please visit www.riverlandmedical.com
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODITâ„¢ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODITâ„¢ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
Rochester Medical Corporation develops, manufactures and markets a line of polyvinyl chloride (PVC)-free and latex-free urinary continence and urine drainage care products for the extended care and acute care markets. The CompanyÍs extended care products
LA CLINICA DE FAMILIA is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.